The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity

Wenqing Mu1,2,3,6, Guang Xu1,3,4,6, Ziying Wei1,4,6, Zhihe Wang1,5, Qin Qin1,4, Li Lin1,4, Lutong Ren1,4, Tingting Liu1,4, Zhe Fang1,4, Yan Yang1,4, Jing Zhao1,4, Junnan Wang1,4, Xiaoyan Zhan1,4, Xiaohe Xiao1,4 and Zhaofang Bai1,4,6

© The Author(s) 2022

Increased medical application of psychotropic drugs raised attention concerning their toxicological effects. In fact, more than 160 psychotropic drugs including antidepressants and antipsychotics, have been shown to cause liver side effects, but the underlying mechanisms are still poorly understood. Here, we discovered that fluoxetine, a common antidepressant, was specifically sensed by NLRP3 inflammasome, whose subsequent activation resulted in the maturation of caspase-1 and IL-1β, as well as gasdermin D (GSDMD) cleavage, which could be completely abrogated by a selective NLRP3 inhibitor MCC950 or Nlrp3 knockout (Nlrp3−/−). Mechanistically, mitochondrial damage and the subsequent mitochondrial reactive oxygen species (mtROS) accumulation were crucial upstream signaling events in fluoxetine-triggered NLRP3 inflammasome activation. In fluoxetine hepatotoxicity models, mice showed the alterations of aminotransferase levels, hepatic inflammation and hepatocyte death in an NLRP3-dependent manner, and MCC950 pretreatment could reverse these side effects of fluoxetine. Notably, we also found that multiple antidepressants, such as amitriptyline, paroxetine, and imipramine, and antipsychotics, such as asenapine, could specifically trigger the NLRP3 inflammasome activation. Collectively, our findings implicate multiple psychotropic drugs may act as danger signals sensed by the NLRP3 inflammasome and result in hepatic injury.

Cell Death Discovery (2022) 8:313; https://doi.org/10.1038/s41420-022-01109-y

INTRODUCTION
Drug-induced liver injury (DILI) is widely regarded as a serious health burden. It is a leading reason of failures in drug development and one of the two most frequent causes for drug withdrawals and restrictions [1, 2]. Although it has been reported that the incidence of DILI ranges from 2 per 100,000 to 19 per 100,000 patient-years, many studies show that the risk of this hepatotoxicity is seriously underestimated [3, 4].

Since exploding rates of mental diseases, as well as subsequent increasing application of psychotropic agents, more and more evidences emerge on their liver-toxic effects. Previous studies have shown that more than 160 psychotropic drugs, including antidepressants and antipsychotics, can cause liver-side effects [5]. As the most common psychotropic drugs, almost all antidepressants are generally considered to cause unpredictable, dose-independent liver injury, even at therapeutic doses, and this hepatotoxicity usually develops between several days and six months during drug intake [6]. Antipsychotics, another common psychotropic drugs, also have been shown to be closely associated with the risk of DILI. The common first-generation antipsychotics, like chlorpromazine, and second-generation antipsychotics, such as risperidone and olanzapine, evidence of hepatotoxicity have been provided in both cases and animal studies [7–11]. Simultaneously, it is worth noting that multiple psychotropic drugs are strongly related to adverse metabolic effects such as diabetes and obesity, which further highlighting the need to recognize the hepatotoxic potential of psychotropic drugs [12, 13]. However, the psychotropic drug-induced DILI is a challenging not only in terms of diagnosis, but also in terms of management.

NLRP3 inflammasome, one of the most representative immune multiprotein platforms, is composed of a sensor NLRP3, adapter ASC, and inflammatory protease caspase-1. This platform is activated in response to diverse molecular patterns [14]. Studies have shown that the NLRP3 inflammasome activation requires two sequential signals: a priming signal and an activation signal. After sensing danger signals, the activated caspase-1 triggers maturation and secretion of proinflammatory cytokine IL-1β and, under certain conditions, to induction of gasdermin D (GSDMD)-mediated pyroptosis [15–17]. As an essential component of host defense, however, the dysregulated NLRP3 inflammasome activity causes uncontrolled inflammation, which underlies multiple diseases, such as gout [18], type 2 diabetes [19], atherosclerosis [20], and idiosyncratic drug-induced liver injury (IDILI) [21]. Growing evidences suggest that excessive activation of the NLRP3 inflammasome is a key risk factor for hepatotoxicity [22], and have

1Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China. 2School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. 3School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China. 4Military Institute of Chinese Materia, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China. 5TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. 6These authors contributed equally: Wenqing Mu, Guang Xu, Ziying Wei. ✉ email: guang_xu@ccmu.edu.cn; pharmacy_302@126.com; baizf2008@hotmail.com

Received: 26 April 2022 Revised: 22 June 2022 Accepted: 28 June 2022
Published online: 09 July 2022

Official journal of CDDpress
been reported that application of the NLRP3 inflammasome blockade can reduce hepatic inflammation and fibrosis in mice [23]. Additionally, studies also have shown the role of NLRP3 in inflammasome in hepatic injury driven by antiepileptic agents such as carbamazepine [24] and antituberculosis drugs such as isoniazid [25].

In our study, we revealed multiple psychotropic drugs including fluoxetine, asenapine, amitriptyline, paroxetine, and imipramine, could act as danger signals to specifically trigger the NLRP3 inflammasome activation accompanied by caspase-1 maturation, IL-1β secretion and GSDMD cleavage. Mitochondrial damage and the subsequent mitochondrial reactive oxygen species (mtROS) accumulation, which were requirements for the NLRP3 inflammasome activation triggered by fluoxetine. These data demonstrated that the NLRP3 inflammasome may serve as a potential target for the development of novel therapeutics for patients with hepatic injury induced by psychotropic drugs.

**RESULTS**

**Multiple psychotropic drugs with the ability to induce DILI trigger the activation of inflammasome**

Given the potential of psychotropic drugs in driving DILI, we were curious about the role of inflammasome in it. Here, seven common clinical psychotropic drugs (asenapine, amitriptyline, mirtazapine, agomelatine, paroxetine, fluoxetine and imipramine) related to liver injury were chosen for testing. As shown in Fig. 1A, B and D, asenapine, amitriptyline, paroxetine, fluoxetine and imipramine directly triggered the inflammasome activation evidenced by caspase-1 maturation and IL-β generation. Meanwhile, the release of lactate dehydrogenase (LDH) (Fig. 1C) (a programmed cell death associated with inflammation) and the production of an inflammasome-independent cytokine TNF-α (Fig. 1E) were observed. The potential of fluoxetine in inducing the secretion of downstream effector cytokines prompted us to conduct a more in-depth study on it.
Multiple psychotropic drugs specifically induce the NLRP3 inflammasome activation

We further investigated the role of fluoxetine (Fig. 2A) on the inflammasome activation. BMDMs were pretreated with LPS followed by fluoxetine stimulation. The results indicated that the production of caspase-1 and IL-1β, and cleavage of GSDMD were triggered by fluoxetine in a dose-dependent manner (Fig. 2B, C and E). Similarly, the release of LDH (Fig. 2D) and the production of TNF-α (Fig. 2F) were associated with the dose of fluoxetine. Meanwhile, LPS-primed BMDMs were stimulated with fluoxetine.
for 1, 3, 6, and 12 h, respectively, and we observed the caspase-1 maturation (Fig. 2G and H), GSDMD cleavage, IL-β generation (Fig. 2G and J), LDH release (Fig. 2I), and TNF-α generation (Fig. 2K) in a time-dependent manner. Furthermore, THP-1 cells were pretreated with PMA for 4 h followed by fluoxetine and MSU stimulation for 12 h. As shown in Fig. 2L, both of fluoxetine and MSU could trigger the maturation of caspase-1 and IL-1β.

Additionally, NLRP3 has the extraordinary capacity of sensing damage-associated molecular patterns (DAMPs) such as MSU, ATP, or silica [26]. Since both antidepressant damage-associated molecular patterns (DAMPs) such as MSU, ATP, or silica [26]. Since both antidepressant fluoxetine and MSU could directly trigger inflammasome activation, we wondered whether the generation of inflammatory cytokines induced by fluoxetine would also occur through the NLRP3 inflammasome. To elucidate this, BMDMs were treated with LPS to provide for the activation of NLRP3 inflammasome by inducing the synthesis of NLRP3 and pro-IL-1β, and then stimulated with fluoxetine, nigericin (Nig), and poly(dAdT). The fluoxetine-induced caspase-1 maturation, IL-1β generation, GSDMD cleavage, and TNF-α accumulation were abrogated in the presence of MCC950 (a specific NLRP3 inflammasome blocker) [27] (Fig. 3A–C). In contrast, AIM2 inflammasome did not appear to be essential for fluoxetine signaling, because the administration of synthetic oligodeoxynucleotide (ODN) [28], a selective and potent blocker of AIM2, completely blocked poly(dAdT)-triggered AIM2 inflammasome activation rather than fluoxetine (Fig. 3A–C). To further clarify the requirement for the NLRP3 inflammasome in antidepressant fluoxetine-induced downstream events. We then assessed the effect of fluoxetine on inflammasome activation in Nlpr3 knockout (Nlpr3−/−) BMDMs. As shown in Fig. 3D and E, the fluoxetine-triggered the maturation of caspase-1 and IL-1β were completely abrogated in Nlpr3−/− BMDMs. Furthermore, the cleavage of GSDMD and production of TNF-α were also blocked in Nlpr3−/− BMDMs (Fig. 3D and F).

Notably, we also found that other psychotropic drugs including asenapine, amitriptyline, paroxetine, and imipramine could trigger inflammasome-dependent cytokines caspase-1 and IL-1β production, and cleavage of GSDMD. Moreover, they could be abrogated by MCC950 pretreatment or Nlrp3 deficiency (Fig. 3G and H, Fig. S1A and B). Likewise, there was an obvious influence on TNF-α production (Fig. S1C and D). Taken together, multiple psychotropic drugs could specifically trigger NLRP3 inflammasome activation to induce the secretion of downstream effector cytokines.

**Mitochondrial damage and mtROS accumulation are crucial molecular signals in fluoxetine-induced NLRP3 inflammasome activation**

Next, we further studied how fluoxetine triggered NLRP3 inflammasome activation. ASC oligomerization seems to be an indispensable step in NLRP3 inflammasome activation [29], offering conditions for the secretion of mature cytokines. As shown in Fig. 4A, fluoxetine triggered dimerization as well as oligomerization of the ASC molecules in a time dependent manner, suggesting that fluoxetine acted upstream events to induce the activation of NLRP3 inflammasome.

The mitochondrial damage and release of the mtROS into cytosol are essential upstream signaling events implicated in the NLRP3 inflammasome activation [30, 31]. Then, we assessed the role of mitochondrial damage in fluoxetine-induced the NLRP3 inflammasome activation. JC-1 staining results indicated that fluoxetine directly triggered mitochondrial damage (Fig. 4B and C). Furthermore, we also wondered whether the accumulation of mtROS was involved in fluoxetine-induced the aberrant activation of the NLRP3 inflammasome. To clarify this, BMDMs were treated with LPS followed by fluoxetine stimulation. The amount of mtROS accumulation was detected by flow cytometry. The results indicated that fluoxetine could induce mtROS generation in a dose-dependent manner (Fig. 4D). We then pretreated LPS-primed BMDMs with N-Acetylcycteine (NAC, a ROS scavenger) [32] to further verify whether the mtROS affected the fluoxetine-triggered NLRP3 inflammasome activation. As shown in Fig. 4E, the accumulation of mtROS was inhibited. Meanwhile, fluoxetine-induced production of caspase-1 and IL-1β were indeed impaired in response to the NAC (Fig. 4F and G). Similarly, the decrease of TNF-α was also observed (Fig. 4H). In summary, these data suggested that the mitochondrial damage and the subsequent mtROS accumulation were indispensable steps in fluoxetine-induced NLRP3 inflammasome activation.

**Fluoxetine induces idiosyncratic hepatotoxicity through NLRP3 inflammasome**

Previous studies have reported that fluoxetine could induce unpredictable, dose-independent hepatotoxicity [33]. Additionally, among the coexisting inflammation factors, LPS is generally considered to be a determinant of susceptibility to IDILI [34]. Here, we simulated IDILI in mice through co-exposing to non-hepatotoxic doses of LPS and fluoxetine, and assessed the role of NLRP3 inflammasome in fluoxetine-driven hepatic injury in vivo. Animals were treated with LPS and subsequently stimulated with fluoxetine. As shown in Fig. 5A–D, fluoxetine alone did not result in any pathological changes compared with the control group. However, compared with other groups, combination of fluoxetine and LPS induced elevation of the levels of serum AST, ALT, IL-1β, and TNF-α. Additionally, TUNEL staining and H&E staining showed that co-exposure to LPS and fluoxetine induced liver inflammation and hepatocyte focal necrosis, which were not occurred in the fluoxetine group and control group (Fig. 5E). Collectively, these data indicate that for the development of idiosyncratic hepatotoxicity in fluoxetine using individuals requires participation of additional inflammation inducers such as LPS. Thus, likelihood of idiosyncratic hepatotoxicity development in fluoxetine-using individuals is higher when they have inflammation-related diseases such as bacterial infection or gout.

**Fluoxetine-induced idiosyncratic hepatic injury could be reversed by MCC950 pretreatment in vivo**

Next, the MCC950 were administered before mice were co-exposed to LPS and fluoxetine, to block the NLRP3 inflammasome activation in vivo. According to the biochemical analysis, we found that pretreatment with MCC950 could dramatically reduce the serum levels of ALT and AST, and suppress the IL-1β production and TNF-α accumulation triggered by LPS/fluoxetine in vivo (Fig. 6A–D). Similarly, the liver inflammation and hepatocyte focal...
necrosis were observed in the LPS/fluoxetine group through TUNEL staining, H&E staining and F4/80 staining, while these situations were obviously improved in the presence of MCC950 (Fig. 6E). These data suggested that the NLRP3 inflammasome played a crucial role in fluoxetine/LPS-driven hepatotoxicity.

DISCUSSION
The psychotropic drug-induced hepatotoxicity is a serious health threat and one of the leading reasons for limiting their development. In our study, the psychotropic drugs fluoxetine [35], asenapine [36], amitriptyline [37], paroxetine [38], and
imipramine [39] with hepatotoxicity reports specifically triggered the NLRP3 inflammasome activation accompanied by the secretion of downstream effector cytokine such as IL-1β, as well as the production of the indirectly regulated cytokine TNF-α. We thought that the production of TNF-α has been indirectly regulated by inflammasome activation, because the inflammasome-dependent inflammatory cytokine IL-1β could induce TNF-α production by activating NF-κB signaling pathway [40, 41]. What supported our inference was that our study Fig. 3C and F showed that the production of TNF-α induced by fluoxetine could be blocked by the selective NLRP3 inhibitor MCC950 pretreatment or Nlrp3 deficiency.

Additionally, the fluoxetine hepatotoxicity models showed that fluoxetine alone could not cause hepatic injury in the absence of LPS. However, in the presence of LPS, fluoxetine induced alterations in liver enzyme levels, hepatic inflammation and hepatocyte death, and this is mediated by the NLRP3 inflammasome. These results suggested that the IDILI related to aberrant activation of the NLRP3 inflammasome caused by fluoxetine may depend on a mild inflammatory state induced by LPS. Consistent with our studies, it has been reported that coexisting inflammatory mediators like LPS could be regarded as the determinants of susceptibility to IDILI [34] and non-hepatotoxic doses of LPS could decrease the threshold for toxicity and/or increase the magnitude of response [42]. Furthermore, given that other psychotropic drugs could also specifically trigger the NLRP3 inflammasome activation, the role of NLRP3 inflammasome in psychotropic drug-driven hepatotoxicity should be considered. Meanwhile, the model of fluoxetine hepatotoxicity has revealed that MCC950 pretreatment could reverse the hepatic injury when co-exposure to LPS and fluoxetine, suggesting that these adverse reactions caused by multiple psychotropic drugs could be rescued or prevented by small molecule inhibitors of the NLRP3 inflammasome.

As studies reported, multiple DAMPs such as monosodium urate (MSU) crystals [43], cholesterol crystals [44], asbestos, and silica [26, 45] are usually regarded as the NLRP3 inflammasome agonist. Nonetheless, they drive various inflammatory-related diseases such as gout [43], atherosclerosis [46], silicosis [26], and even DILI [47] by inducing aberrant activation of the NLRP3 inflammasome. Consistent with these studies, our findings showed that multiple psychotropic drugs directly triggered aberrant activation of the NLRP3 inflammasome, indicating that in certain special cases, they can be regarded as exogenous DAMPs, triggering aberrant response of the innate immune and resulting in idiosyncratic hepatotoxicity.

Interestingly, the effects of selective serotonin reuptake inhibitors (SSRIs) on inflammatory response are contradictory since these agents act either as anti- or pro-inflammatory. As the most common SSRIs, fluoxetine has been reported to play an anti- or pro-inflammatory role in microglia related to the quality of the living environment [48]. Additionally, it is worth noting that the response of fluoxetine to inflammation in different tissues is also paradoxical. For example, fluoxetine affects depression by inhibiting the activation of NLRP3 inflammasome in microglia [49]. Furthermore, fluoxetine mitigates NLRP3 inflammasome and caspase-1 activation through autophagy activation after subarachnoid hemorrhage (SAH) to treat early brain injury [50]. In contrast, fluoxetine treatment shows a marked pro-inflammatory effect in liver tissue. The previous study has shown that fluoxetine treatment can lead to liver inflammation and oxidative stress [33]. Other studies also have shown that fluoxetine induces portal zone inflammation, lobular inflammation, and hepatomegaly [51, 52]. Consistent with these studies, our work suggest that fluoxetine induces idiosyncratic hepatotoxicity by triggering aberrant activation of the NLRP3 inflammasome. Although we still poorly understood the underlying molecular mechanisms of fluoxetine’s differential response in inflammation, monitoring of potential liver injury during fluoxetine treatment appears to be warranted.

In summary, our studies demonstrate that fluoxetine and other psychotropic drugs with similar effects can act as exogenous DAMPs directly trigger the NLRP3 inflammasome activation accompanied by caspase-1 activation, IL-1β secretion and GSDMD mediated pyroptosis. Meanwhile, mitochondria damage and mtROS accumulation as the crucial molecular signals that are conducive to fluoxetine trigger its activation. In this way, combined with selective small molecule inhibitors of NLRP3 inflammasome may be a valid therapeutic strategy for the treatment of liver injury caused by multiple psychotropic drugs.

MATERIALS AND METHODS

Mice

Wild-type (WT) female C57BL/6 mice (eight-week-old) in the study were obtained from SPF Biotechnology Co., Ltd of Beijing, China. Female Nlrp3–/– mice were supported by Dr. Tao Li from National Center of Biomedical Analysis (Beijing, China). All mice were maintained under a pathogen-free condition (22 ± 2 °C) and held under a 12-h dark/light cycle. We tried our best to minimize the suffering as well as the number of animals used. When assessing experimental outcomes, the investigators were blinded to the treatments.

Chemicals and antibodies

The chemicals and antibodies in our study were listed in Supplemental Table 1. All small molecular compounds were dissolved in DMSO.

Cell preparation and culture

BMDMs were isolated and collected from the Nlrp3−/− mice or WT mice using a standard reverse perfusion procedure and then cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, as well as murine recombinant mouse macrophage colony-stimulating factor (MCSF; 50 ng/mL). Additionally, human THP-1 cells, which were a gift from Dr. Tao Li from NCBA, were incubated in Roswell Park Memorial Institute (RPMI) 1640 medium (1% penicillin/streptomycin and 10% FBS) and primed with 100 nmol PMA for 6 h. Cells were kept in a humidified 5% (v/v) CO2 incubator at 37 °C.

Inflammasome activation assay

To assess the activation of the inflammasome, WT and/or Nlrp3−/– BMDMs (1.2 × 105 cells/mL) were incubated in 12-well plates overnight. Next, cells were pretreated with ultrapure LPS (50 ng/mL) for 4 h and then stimulated...
Fig. 4 Mitochondrial damage and mtROS accumulation are crucial molecular signals for fluoxetine-induced NLRP3 inflammasome activation. A The oligomerization of ASC after DSS crosslinking in WCL was measured by western blotting. B, C The mitochondrial damage was assessed using a JC-1 mitochondrial membrane potential assay kit. D LPS-primed BMDMs were stimulated with fluoxetine for 6 h and the mtROS content was measured by flow cytometry. E–H LPS-primed BMDMs were pretreated with NAC and then treated with fluoxetine (40 μM) for 6 h, the mtROS content (E) was measured by flow cytometry. The expression levels of cleaved caspase-1 and IL-1β in SN (F) were detected by western blotting and using ELISA kits to detect the secretion of IL-1β (G) and generation of TNF-α (H) in SN. Data are shown as the mean ± SEM from three biological samples; *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant. One-Way ANOVA analysis followed by Dunnett’s post hoc test.
with various psychotropic drugs (asenapine, amitriptyline, mirtazapine, agomelatine, paroxetine, fluoxetine, and imipramine, 40 \( \mu \)M) for 12 h, respectively. The inflammasome-related downstream effector cytokines were detected.

Caspase assay
Activity of caspase-1 in cell supernatants was measured by Caspase-Glo 1 reagent. The experimental protocol of activity of the caspase-1 assay was similar to described previously [53, 54].

Immunoblotting
After psychotropic drugs treatment, the cell supernatants were collected and then trichloroacetic acid was added to precipitate proteins. The method of western blotting analysis has been described previously [55].

LDH release
BMDMs were pretreated with LPS and then treated with psychotropic drugs for twelve hours. Then, the release of LDH in cell culture supernatants was detected using a LDH cytotoxicity assay kit.

Enzyme-linked immunosorbent assay (ELISA)
The levels of TNF-\( \alpha \) and IL-1\( \beta \) in cell supernatants and serum were measured using Mouse ELISA Kits, which were performed under the manufacturer’s instructions.

ASC oligomerization
LPS-primed BMDMs were stimulated with fluoxetine (40 \( \mu \)M) for 1, 3, 6, and 12 h, respectively, and then lysed with Triton Buffer [56] for 15 min. Next, these samples were collected and centrifuged at 6500 g for 15 min (4 °C).

with various psychotropic drugs (asenapine, amitriptyline, mirtazapine, agomelatine, paroxetine, fluoxetine, and imipramine, 40 \( \mu \)M) for 12 h, respectively. The inflammasome-related downstream effector cytokines were detected.

Caspase assay
Activity of caspase-1 in cell supernatants was measured by Caspase-Glo 1 reagent. The experimental protocol of activity of the caspase-1 assay was similar to described previously [53, 54].

Immunoblotting
After psychotropic drugs treatment, the cell supernatants were collected and then trichloroacetic acid was added to precipitate proteins. The method of western blotting analysis has been described previously [55].

LDH release
BMDMs were pretreated with LPS and then treated with psychotropic drugs for twelve hours. Then, the release of LDH in cell culture supernatants was detected using a LDH cytotoxicity assay kit.

Enzyme-linked immunosorbent assay (ELISA)
The levels of TNF-\( \alpha \) and IL-1\( \beta \) in cell supernatants and serum were measured using Mouse ELISA Kits, which were performed under the manufacturer’s instructions.

ASC oligomerization
LPS-primed BMDMs were stimulated with fluoxetine (40 \( \mu \)M) for 1, 3, 6, and 12 h, respectively, and then lysed with Triton Buffer [56] for 15 min. Next, these samples were collected and centrifuged at 6500 g for 15 min (4 °C).
The supernatants were used as whole-cell lysates (WCL) and the pellet were washed and resuspended with 200 μL phosphate-buffered saline (PBS) and then cross-linked with 4 mM disuccinimidyl suberate (DSS) at 37 °C for 30 min with rotation. After centrifuging at 6500 g for 15 min, the cross-linked pellets were collected and resuspended in 1 x SDS loading buffer for western blotting assay.

Measurement of mitochondrial damage and mtROS measurement

The JC-1 mitochondrial membrane potential assay kits were used to assess the damage of mitochondrial. BMDMs in diameter culture dish tubes (100 mm) were pretreated with LPS for four hours. Then, the cells were transferred to 1.5 mL tubes and stimulated with fluoxetine for 6 h and then incubated with JC-1 (10 μM) at 37 °C for fifteen minutes. After cells were washed with PBS twice and resuspended with 200 μL PBS, flow cytometry was used to evaluate the mitochondrial damage. Similarly, to assess the fluoxetine-induced mtROS accumulation, BMDMs in the diameter culture dish tubes were treated with LPS and then transferred to tubes followed by fluoxetine stimulation for six hours. Next, the samples were washed with hank’s balanced salt solution (HBSS) twice and stained with 4 mM MitoSOX Red mitochondrial superoxide dismutase indicator for fifteen minutes. After staining and washing, 200 μL HBSS were added to resuspend cells and the production of mtROS was conducted by flow cytometry.

Biochemical analysis

The mouse serum levels of AST and ALT were evaluated with commercially available kits (Nanjing Jiancheng Bioengineering Institute).
Stimulation with fluoxetine in vivo
LPS (2 mg/kg) or PBS vehicles was administered to the WT C57BL/6 mice (female; 8-week-old; n = 6/group) via tail vein for two hours. Then, the mice were injected intraperitoneally with fluoxetine (10 mg/kg or 20 mg/kg) or its carrier (PBS) six hours before mouse serum and liver tissue were collected. The serum levels of ALT or AST was measured with GPT or GOT kits and the serum levels of TNF-α or IL-1β was assessed with the Mouse ELISA kits. Simultaneously, using hematoxylin and eosin (H&E) staining and TUNEL staining to evaluate the injury of liver tissue.

Combination of MCC950 and fluoxetine
The WT C57BL/6 mice (female; 8-week-old; n = 5 LPS and LPS/FLU groups, n = 6 other groups) were injected intraperitoneally with 50 mg/kg MCC950 or PBS. One hour later, LPS (2 mg/kg) or its carrier were given via the tail vein and then fluoxetine (20 mg/kg) or PBS were administrated via intraperitoneal injection. After 6 h, the mouse serum levels of ALT, AST, IL-1β, and TNF-α were detected by corresponding kits, and the liver tissues injury were assessed by H&E staining, TUNEL staining and F4/80 staining.

Statistical analyses
Excel was used for statistics and GraphPad Prism 6 (a GraphPad Software) was applied for analysis. All of the results were presented as the mean ± SEM. Comparisons were performed by One-Way ANOVA analysis (multigroups) or Student’s t-test (two groups). The difference was considered statistically significant when P < 0.05.

DATA AVAILABILITY
All data will be made available upon request.

REFERENCES
1. Chalasani NP, Hayashi PH, Bonkovsky HL, Fontana RJ, Agarwal VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66.
2. Billioti de Gage S, Collin C, Le-Tri T, Pariente A, Bégaud B, Verdoux H, et al. Antidepressants. Drugs: Basic Pharmacology, Toxicology and Clinical Use. 2002;36:451–5.
3. Kgiamati S, Chalasani NP, Hayashi PH, Ahrén B, Bonkovsky HL, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66.
4. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2008;57:865–72.
5. Su Q, Wang Y, Hua J, Hua J, Liang F, Tang C, et al. Antituberculosis Drugs Blocks ASC Oligomerization and Inhibits NLRP3 Inflammation. Front Immunol. 2019;10:2791.
6. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.
7. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20:3328.
8. Wu X, Zhang H, Qi W, Zhang Y, Li J, Li Z, et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death Dis. 2018;9:9171.
9. Elgebaly HA, Mosa NM, Allack M, El-Massy KF, El-Ghobair AH, Al Hroob AM, et al. Olive oil and leaf extract prevent fluoxetine-induced hepatotoxicity by attenuating oxidative stress, inflammation and apoptosis. Biomedicine Pharmacother = Biomedicin Pharmacotheraphy. 2018;98:446–53.
10. Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: An Overview of Mechanisms of Activation and Regulation. Nat Rev Dis Prim. 2019;5:69.
11. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatric. 2014;171:404–15.
12. Odeh M, Misselevich I, Boss JH, Oliven A. Severe hepatotoxicity with jaundice associated with paroxetine. Am J Gastroenterol. 2001;96:2494–6.
13. Chang GR, Hou PH, Wang CM, Lin JW, Lin WL, Lin TC, et al. Immune Precipitate Activates Nonalcoholic Fatty Liver Disease, Renal Impairment, Diabetic Retinopathy, Insulin Resistance, and Urinary Chromium Loss in Obese Mice. Vet Sci. 2018;5:135–51.
14. Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood. 1992;79:2364–9.
15. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50.
16. Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury. Current Status. Crit Rev Toxicol. 2011;41:723–39.
17. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NLRP3 inflammasome. Nature. 2006;440:341–47.
ACKNOWLEDGEMENTS
We wish to thank Dr. Tao Li for his support in providing Nlrp3−/− mice and THP-1 cells. This study was granted by National Natural Science Foundation of China (81630100, 81874368), Beijing Nova Program (Z18110006218001), Chinese Postdoctoral Science Foundation (2020M673676), Youth Foundation of Chinese PLA General Hospital (QNF19065).

AUTHOR CONTRIBUTIONS
WQM, GX, XHX and ZFB conceived and designed the study. WQM wrote the manuscript. WQM and ZYW analyzed the data and revised the manuscript. WQM, ZLW and QQ performed the experiment. WQM, LL, LTR, TTL and ZEF verified the data. YY, JZ and JNW provided assistant to the mice model. XYZ provided technical assistance. XHX, ZFB and GX supervised the study and final proofed the manuscript. All authors read and approved the final version of the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL
All of our experimental protocols have been approved by the Animal Ethics Committee of the Fifth Medical Center, Chinese People’s Liberation Army (PLA) General Hospital (Beijing, China).

CONSENT FOR PUBLICATION
All authors have read and agreed to the published version of the manuscript.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-022-01109-y.

Correspondence and requests for materials should be addressed to Guang Xu, Xiaoxue Xiao or Zhaofang Bai.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022